AB RESP-E
COMPOSITION
ACEBROPHYLLINE..............100mg
ERDOSTEINE...........300mg
Acebrophylline 100 mg + Erdosteine 300 mg Acebrophylline— mucoregulator ·
bronchodilator Erdosteine— mucolytic · antioxidant
Chronic bronchitis and COPD
exacerbations are driven by thick, adherent mucus, narrowed airways, and
ongoing oxidative airway
inflammation. This combination pairs a xanthine-derivative mucoregulator with a thiol
mucolytic so that airway clearance and airflow are addressed together, rather than one at a time.
Theophylline-7-acetate + ambroxol moiety
·
Relaxes bronchial smooth muscle by inhibiting phosphodiesterase III/IV, raising intracellular cAMP
·
Stimulates pulmonary surfactant production, easing mucus expulsion
·
Suppresses phospholipase A₂, reducing leukotriene and TNF-driven inflammation
Thiolactone pro-drug
·
Active thiol metabolites cleave
mucus disulfide bonds,
lowering viscosity
·
Scavenges free radicals from smoke and inflammatory stress, protecting airway epithelium
·
Improves antibiotic penetration into sputum during infective exacerbations
·
Reduce bacterial
adhesion to the epithelial cells.
Net effect: easier expectoration, reduced bronchial
hyper-responsiveness, and antioxidant
cover during acute exacerbations of
chronic bronchitis and COPD.
Each film-coated Bilayered tablet contains:
|
Active ingredient |
Strength |
Role |
|
Acebrophylline |
100 mg |
Mucoregulator & bronchodilator |
|
Erdosteine |
300 mg |
Mucolytic & antioxidant |
·
Acute exacerbations of chronic bronchitis with thick, difficult-to-clear sputum
·
Chronic
obstructive pulmonary disease
(COPD) with persistent productive cough
·
Bronchial asthma
with mucus hypersecretion, as an adjunct
to bronchodilator therapy
·
Adjunct to antibiotic therapy
during infective exacerbations, to aid sputum
penetration
·
Known hypersensitivity to ambroxol,
theophylline/xanthine derivatives, or erdosteine
·
Active peptic ulcer disease
·
Severe renal impairment (creatinine clearance < 25 mL/min) or hepatic cirrhosis
·
Recent myocardial infarction, hemodynamic instability, or significant arrhythmia
·
Pregnancy and lactation, unless benefit clearly
outweighs risk
To be taken strictly as prescribed. Final
posology and duration
are at the physician's discretion.
1.
Adults
- One tablet twice daily, after
food, with a full glass
of water.
2. Duration - Typically continued through the acute exacerbation; courses beyond 10 days should be physician-reviewed, per
erdosteine's labelled posology.
3. Hepatic impairment - Use with caution; avoid exceeding recommended daily exposure in mild hepatic impairment, and avoid entirely in cirrhosis.
4. Elderly &
renal impairment - Dose adjustment may be required; avoid if creatinine clearance is below 25 mL/min.
Gastrointestinal discomfort, nausea,
heartburn, loss of appetite,
headache, and mild drowsiness. Most are
dose-related and self-limiting.
Rash,
itching, or breathing difficulty warrant discontinuation. Fever or chills during therapy
should prompt immediate
medical review.
Caution
with concurrent xanthine derivatives, potassium-losing diuretics (e.g. furosemide),
and hormonal contraceptives, which may alter clearance.
Not established for use
in children. Caution advised
in patients under 18 and in those with a
history of stomach ulcers.
For the use of
a Registered Medical Practitioner, Hospital, or Laboratory only. This brochure
summarizes published pharmacological and prescribing information on acebrophylline and erdosteine and is intended
as a formulation overview
— it does not
replace the approved package insert.
Prescribers should confirm current indications, contraindications, and dosing
against the product's official prescribing information before use.
AB-RESP E is marketed by Exmo Biogenics Pvt Ltd